August 7, 2025 – Talk Bio

Strand Therapeutics Raises $153M Series B to Advance mRNA Tumor Drugs

4 hours ago talkbio0Tagged Big Pharma investors, biotech financing, Clinical Trials, Genomic Orientation, interleukin-12, mRNA cancer, Series B funding, Solid Neoplasm, STX-001

Strand Therapeutics; Series B funding; mRNA cancer therapy; STX-001; IL-12; solid tumors; Big Pharma investors; clinical trial results; biotech financing

Amid MFN Talks, Lilly Chief Warns US Adoption of International Drug Prices Could Bring ‘Worst of Two Worlds’

4 hours ago talkbio0Tagged Cautionary Warning, Chief, Does speak, Drug Industry, drug price, Eli Lilly, International Drug Prices, MFN, Policy, U.S.

Lilly chief; MFN talks; international drug prices; US drug pricing; pharmaceutical industry; policy warning

Minghui Raises $131M to Advance PD-1xVEGF Bispecific Antibody Program

4 hours ago talkbio0Tagged Chinese biotech, Clinical Development, Inhibitor, Janus kinase, Minghui, Neoplasms, PD-1xVEGF bispecific, pre-IPO ', therapeutic autologous dendritic cells, trials

Minghui; Chinese biotech; PD-1xVEGF bispecific; fundraising; pre-IPO; ADC trials; JAK inhibitor; oncology; clinical development

Elevidys Sales Surge in Sarepta Q2 2025 Despite Safety Concerns

4 hours ago talkbio0Tagged ELEVIDYS, gene therapy, Pauses, Performance, Safety Issues, Sales - occupational activity, United States Food and Drug Administration

Sarepta Therapeutics; Elevidys; Q2 2025; gene therapy; sales performance; FDA; safety issues; shipment pause

Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027

8 hours ago talkbio0Tagged 2025, debt, decline, Efficiency, ELEVIDYS, Financial cost, financial results, Financial savings, Measures, Muscular Dystrophy, Duchenne, restructuring, United States Food and Drug Administration

Sarepta Therapeutics; debt 2027; efficiency measures; ELEVIDYS; cost savings; restructuring; financial results 2025; FDA; Duchenne muscular dystrophy; stock decline

Execution, Execution, Execution: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline

8 hours ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, Incretins, Leadership Change, Market, Maziar Mike Doustdar, Nordisk, Obesity, Ozempic, pipeline, Wegovy

Novo Nordisk; Maziar Mike Doustdar; obesity; diabetes; pipeline cuts; GLP-1 drugs; Wegovy; Ozempic; incretin market; leadership change

FDA Grants Accelerated Approval to Jazz’s Dordaviprone (Modeyso), the First Treatment for Ultra-Rare Brain Tumor

8 hours ago talkbio0Tagged Accelerated, Approved, Brain Neoplasms, Chimerix acquisition, Confirmatory Trial, Dordaviprone, midline glioma, Modeyso, pediatric brain cancer, United States Food and Drug Administration

Dordaviprone; Modeyso; FDA approval; H3 K27M-mutant diffuse midline glioma; ultra-rare brain tumor; Jazz Pharmaceuticals; accelerated approval; pediatric brain cancer; Chimerix acquisition; confirmatory trial

BioNTech to Cut 90 More US Jobs Amid Strategic Realignment

14 hours ago talkbio0Tagged BioNTech, Cambridge, Cell Therapy, Gaithersburg, layoffs, Market, pipeline focus, post-COVID, R&D, strategic alignment

BioNTech; layoffs; job cuts; R&D; pipeline focus; Gaithersburg; Cambridge; cell therapy; post-COVID market; strategic alignment

XtalPi and DoveTree Announce Landmark $6 Billion AI-Powered Drug Discovery Collaboration

14 hours ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Collaboration, Dosage Forms, DoveTree Medicines, Drug Discovery, Gregory Verdine, Immunology, Metabolic Diseases, milestone payments, Neoplasms, Neurology speciality, Robotics, royalties, upfront payment, XtalPi

XtalPi; DoveTree Medicines; AI drug discovery; robotics; pharmaceutical R&D; Gregory Verdine; oncology; immunology; neurology; metabolic diseases; collaboration; upfront payment; milestone payments; royalties